<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00557102</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000574153</org_study_id>
    <secondary_id>CHUG-ERBIFORT</secondary_id>
    <secondary_id>INCA-RECF0316</secondary_id>
    <secondary_id>EUDRACT-2007-000357-54</secondary_id>
    <nct_id>NCT00557102</nct_id>
  </id_info>
  <brief_title>Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung</brief_title>
  <acronym>ERBIFORT</acronym>
  <official_title>Frontline Chemotherapy &quot;Reinforced&quot; for Cancers of the Colon and Rectum With Potentially Resectable Hepatic and/or Pulmonary Metastases: Association of FOLFIRI and ERBITUX</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute, France</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different&#xD;
      ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and&#xD;
      help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as&#xD;
      irinotecan, leucovorin, and fluorouracil, work in different ways to stop the growth of tumor&#xD;
      cells, either by killing the cells or by stopping them from dividing. Giving cetuximab&#xD;
      together with combination chemotherapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving cetuximab together with combination&#xD;
      chemotherapy works as first-line therapy in treating patients with colorectal cancer that has&#xD;
      spread to the liver and/or lung.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the tumor response rate in patients with colorectal cancer and hepatic and/or&#xD;
           pulmonary metastases treated with cetuximab and FOLFIRI chemotherapy comprising&#xD;
           irinotecan hydrochloride, leucovorin calcium, and fluorouracil as first-line therapy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the rate of resectability in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the overall and disease-free survival of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the tolerability of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive cetuximab IV over 60-120 minutes on days 1 and 8. Patients also receive&#xD;
      FOLFIRI chemotherapy comprising irinotecan hydrochloride IV over 90 minutes and leucovorin&#xD;
      calcium IV over 2 hours on day 1 and fluorouracil IV continuously over 48 hours on days 1 and&#xD;
      2. Patients with 7/6 or 7/7 genotypes also receive filgrastim (G-CSF) as primary prophylaxis&#xD;
      (patients with 6/6 genotypes receive G-CSF as secondary prophylaxis). Treatment repeats every&#xD;
      2 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.&#xD;
      Within 6 weeks after the completion of cetuximab and FOLFIRI chemotherapy, patients with&#xD;
      responding disease undergo surgical resection of visceral metastases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor response rate</measure>
    <time_frame>From baseline to end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of resectability</measure>
    <time_frame>From baseline to end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall and disease-free survival</measure>
    <time_frame>From baseline to end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>From baseline to end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>cetuximab, FOLFIRI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <arm_group_label>cetuximab, FOLFIRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <arm_group_label>cetuximab, FOLFIRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <arm_group_label>cetuximab, FOLFIRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <arm_group_label>cetuximab, FOLFIRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <arm_group_label>cetuximab, FOLFIRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the colon or rectum&#xD;
&#xD;
          -  Must have synchronous or metasynchronous unresectable hepatic metastases&#xD;
&#xD;
               -  Less than 8 hepatic metastases&#xD;
&#xD;
               -  Less than 6 segments of liver involvement with metastases&#xD;
&#xD;
          -  No more than 2 potentially resectable extrahepatic (e.g., pulmonary) metastases&#xD;
&#xD;
          -  Patients with visceral metastases that are potentially resectable after chemotherapy&#xD;
             (i.e., tumor regression) are eligible&#xD;
&#xD;
          -  At least 1 measurable metastasis by CT scan or MRI&#xD;
&#xD;
          -  No brain metastases, bone metastases, or carcinomatous meningitis&#xD;
&#xD;
          -  No celiac lymph node involvement or peritoneal cancer&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status 0-1&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  ANC ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  PT rate &gt; 70%&#xD;
&#xD;
          -  Bilirubin &lt; 30 μmol/L&#xD;
&#xD;
          -  Creatinine &lt; 130 μmol/L&#xD;
&#xD;
          -  Creatinine clearance &gt; 60 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  No other prior malignancy except basal cell skin cancer or carcinoma in situ of the&#xD;
             cervix&#xD;
&#xD;
          -  No severe unstable angina&#xD;
&#xD;
          -  No symptomatic heart failure&#xD;
&#xD;
          -  No other concurrent illness&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  At least 3 months since prior adjuvant anticancer chemotherapy&#xD;
&#xD;
          -  No concurrent participation in another clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Marc Phelip, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Grenoble - Hopital Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>November 9, 2007</study_first_submitted>
  <study_first_submitted_qc>November 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 12, 2007</study_first_posted>
  <last_update_submitted>December 10, 2012</last_update_submitted>
  <last_update_submitted_qc>December 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>liver metastases</keyword>
  <keyword>lung metastases</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

